R&D focus shifted to proteoform applications due to strong customer demand and technical progress, with first revenue recognized from grants and early access. Operating expenses declined, cash runway extends into 2028, and commercial launch of new assays and platform is on track for 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.